Opendata, web and dolomites

SELMA SIGNED

Trial Ready Small Vessel MRI Markers: Proof of Concept

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SELMA project word cloud

Explore the words cloud of the SELMA project. It provides you a very rough idea of what is the project "SELMA" about.

proof    trials    ambition    irreversible    measuring    group    erc    abnormalities    gap    pilot    selma    platforms    337333    industry    newly    invasive    velocity    quality    clinically    stroke    hallmark    experiments    imaging    damage    smallvesselmri    treatment    solution    reflect    vascular    serious    individuals    engagement    flow    shift    society    hampers    blood    healthcare    trial    diseases    first    scanners    pulse    reproducibility    scan    automated    healthy    rescan    secondary    drugs    brain    data    themselves    time    sequences    svd    problem    stiffness    15    software    ready    vessel    lack    reflecting    informs    administration    ubiquitous    pharmaceutical    small    dementia    macroscopic    bridge    3t    itself    patients    agent    pulsation    35    life    ageing    acute    7t    cerebral    mri    vessels    clinical    port    business    perforating    biomarkers    yielded    plan    image    paradigm    markers    tool    drug    disease   

Project "SELMA" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAIR MEDISCH CENTRUM UTRECHT 

Organization address
address: HEIDELBERGLAAN 100
city: UTRECHT
postcode: 3584 CX
website: www.umcutrecht.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 149˙979 €
 EC max contribution 149˙979 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) coordinator 149˙979.00

Map

 Project objective

Problem: Cerebral small vessel disease (SVD) is a hallmark of serious brain diseases such as acute stroke and dementia. It has a major impact on society, since it affects quality of life of many ageing individuals, and increasingly challenges the healthcare resources. Current image-based biomarkers do not reflect SVD itself, but rather macroscopic, irreversible brain damage, secondary to the abnormalities of the small vessels. This greatly hampers development of new drugs as clinical trials lack effective biomarkers directly reflecting SVD. Solution: The SmallVesselMRI ERC project (337333), yielded 7T MRI methods with the potential to offer a paradigm shift in SVD research. We have developed new MRI measures that, for the first time, allow non-invasive assessment of the condition of the small vessels themselves, including blood flow velocity pulsation in small perforating vessels, which informs on vessel stiffness. The current proof-of-concept project ‘trial-ready Small vEsseL MRI MArkers (SELMA) aims to make these novel promising vascular parameters ready for use in phase II/III clinical trials. Our ambition is to bridge the gap between high end imaging research platforms and widespread clinical MRI, in order to enable drug-target engagement studies in clinical trials for newly developed drugs. SELMA will: 1) Port the small-vessel 7T MRI pulse sequences to clinically ubiquitous 3T MRI scanners. 2) Develop a software tool that can provide robust, automated data analysis. 3) Determine the reproducibility of the SELMA biomarkers in a group of 35 healthy individuals with scan-rescan experiments. 4) Provide clinical proof of concept by a pilot study in 15 patients with SVD, measuring the vascular parameters before and after administration of a pharmaceutical agent. Using results of our proof of concept study, we will develop a business plan to approach the pharmaceutical industry to change the paradigm in drug development for SVD treatment.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SELMA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SELMA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

Neurovulnerability (2019)

Molecular mechanisms underlying selective neuronal death in motor neuron diseases

Read More  

TroyCAN (2020)

Redefining the esophageal stem cell niche – towards targeting of squamous cell carcinoma

Read More  

InsideChromatin (2019)

Towards Realistic Modelling of Nucleosome Organization Inside Functional Chromatin Domains

Read More